Stay updated with breaking news from Humacyte board. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Humacyte, Inc. (NASDAQ:HUMA – Get Rating) CEO Laura E. Niklason sold 2,625,000 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $2.75, for a total transaction of $7,218,750.00. Following the completion of the sale, the chief executive officer now directly owns […] ....
12.05.2023 - - $40 million upfront, $20 million upon FDA acceptance of HAV BLA in vascular trauma, $40 million upon FDA approval of HAV in vascular trauma, $50 million upon achievement of certain sales milestones, and $10 million equity option - - Proceeds to . Seite 1 ....
DURHAM, N.C., May 05, 2023 Humacyte, Inc. , a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, will release its. | May 5, 2023 ....
Humacyte, Inc. (NASDAQ:HUMAW – Get Rating) saw a significant increase in short interest in April. As of April 15th, there was short interest totalling 16,600 shares, an increase of 7.1% from the March 31st total of 15,500 shares. Based on an average daily trading volume, of 6,800 shares, the short-interest ratio is currently 2.4 days. […] ....
Humacyte, Inc. (NASDAQ:HUMAW – Get Rating) was the recipient of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 16,600 shares, a growth of 7.1% from the March 31st total of 15,500 shares. Based on an average daily trading volume, of 6,800 shares, the […] ....